GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Medicilon Inc (SHSE:688202) » Definitions » Debt-to-Equity

Shanghai Medicilon (SHSE:688202) Debt-to-Equity : 0.14 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Shanghai Medicilon Debt-to-Equity?

Shanghai Medicilon's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥324 Mil. Shanghai Medicilon's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥15 Mil. Shanghai Medicilon's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥2,458 Mil. Shanghai Medicilon's debt to equity for the quarter that ended in Mar. 2024 was 0.14.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Shanghai Medicilon's Debt-to-Equity or its related term are showing as below:

SHSE:688202' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03   Med: 0.12   Max: 0.43
Current: 0.14

During the past 10 years, the highest Debt-to-Equity Ratio of Shanghai Medicilon was 0.43. The lowest was 0.03. And the median was 0.12.

SHSE:688202's Debt-to-Equity is ranked worse than
50.09% of 1070 companies
in the Biotechnology industry
Industry Median: 0.145 vs SHSE:688202: 0.14

Shanghai Medicilon Debt-to-Equity Historical Data

The historical data trend for Shanghai Medicilon's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Medicilon Debt-to-Equity Chart

Shanghai Medicilon Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.05 0.03 0.17 0.15

Shanghai Medicilon Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.27 0.18 0.15 0.14

Competitive Comparison of Shanghai Medicilon's Debt-to-Equity

For the Biotechnology subindustry, Shanghai Medicilon's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Medicilon's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Medicilon's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Shanghai Medicilon's Debt-to-Equity falls into.



Shanghai Medicilon Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Shanghai Medicilon's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Shanghai Medicilon's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Medicilon  (SHSE:688202) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Shanghai Medicilon Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Shanghai Medicilon's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Medicilon (SHSE:688202) Business Description

Traded in Other Exchanges
N/A
Address
Lane 67, Libing Road, Building 5, Pilot Free Trade Zone, Shanghai, CHN, 201299
Shanghai Medicilon Inc is a comprehensive biomedical research and developemnt service company. It provides a full range of one-stop new drug development services for pharmaceutical companies and research institutions around the world in line with domestic and international reporting standards.

Shanghai Medicilon (SHSE:688202) Headlines

No Headlines